Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study - Peng, Zhi; Liu, Tianshu; Wei, Jia; Wang, Airong; He, Yifu; Yang, Liuzhong; Zhang, Xizhi; Fan, Nanfeng; Luo, Suxia; Li, Zhen; Gu, Kangsheng; Lu, Jianwei; et al. (Cancer communications (London, England), 2021)
Keywords: Antibodies; Antibodies, Monoclonal, Humanized; antibody‐drug conjugate; Cancer therapies; Chemotherapy; Disease control; Documentation; Drug dosages; Drug withdrawal; Epidermal growth factor; Esophagogastric Junction; FDA approval; Gastric cancer; HER2‐overexpressing; Humans; Immunotherapy; Metastasis; Original; Patients; phase II clinical trial; Radiation therapy; RC48; Receptor, ErbB-2 - genetics; Response rates; Stomach Neoplasms - drug therapy; Stomach Neoplasms - genetics; third‐line therapy; Tumors; Vaccines; United States--US; China; third-line therapy; HER2-overexpressing; RC48; antibody-drug conjugate; gastric cancer; phase II clinical trial